• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Biogen's Aduhelm still has blockbuster potential if everything breaks right: analyst

cafead

Administrator
Staff member
  • cafead   Mar 04, 2022 at 10:02: AM
via Amid a torrent of negative press for Biogen’s troubled Alzheimer's disease treatment Aduhelm, there remains a significant community of patients and doctors who are hoping to use and prescribe the drug, a team of analysts found.

article source
 

<